CA2937305C - Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells - Google Patents

Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells Download PDF

Info

Publication number
CA2937305C
CA2937305C CA2937305A CA2937305A CA2937305C CA 2937305 C CA2937305 C CA 2937305C CA 2937305 A CA2937305 A CA 2937305A CA 2937305 A CA2937305 A CA 2937305A CA 2937305 C CA2937305 C CA 2937305C
Authority
CA
Canada
Prior art keywords
cells
diseases
fold
msc
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2937305A
Other languages
English (en)
French (fr)
Other versions
CA2937305A1 (en
Inventor
Yael GOTHELF
Yosef Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brainstorm Cell Therapeutics Ltd
Original Assignee
Brainstorm Cell Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brainstorm Cell Therapeutics Ltd filed Critical Brainstorm Cell Therapeutics Ltd
Publication of CA2937305A1 publication Critical patent/CA2937305A1/en
Application granted granted Critical
Publication of CA2937305C publication Critical patent/CA2937305C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073Stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/115Basic fibroblast growth factor (bFGF, FGF-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/13Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/135Platelet-derived growth factor [PDGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/195Heregulin, neu differentiation factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/58Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
CA2937305A 2014-02-11 2015-02-11 Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells Expired - Fee Related CA2937305C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461938172P 2014-02-11 2014-02-11
US61/938,172 2014-02-11
PCT/IL2015/050159 WO2015121859A1 (en) 2014-02-11 2015-02-11 Method of qualifying cells

Publications (2)

Publication Number Publication Date
CA2937305A1 CA2937305A1 (en) 2015-08-20
CA2937305C true CA2937305C (en) 2020-12-15

Family

ID=52682791

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2937305A Expired - Fee Related CA2937305C (en) 2014-02-11 2015-02-11 Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells

Country Status (7)

Country Link
US (1) US10564149B2 (enExample)
EP (1) EP3105587B1 (enExample)
JP (1) JP6628253B2 (enExample)
BR (1) BR112016018489A2 (enExample)
CA (1) CA2937305C (enExample)
IL (1) IL246943B (enExample)
WO (1) WO2015121859A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014024183A1 (en) 2012-08-06 2014-02-13 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
CA2937305C (en) 2014-02-11 2020-12-15 Brainstorm Cell Therapeutics Ltd. Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells
US11707488B2 (en) 2015-08-28 2023-07-25 Rohto Pharmaceutical Co., Ltd. ROR1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ROR1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating disease using ROR1-positive mesenchymal stem cells
JP6153653B2 (ja) * 2015-12-07 2017-06-28 株式会社Cells Power 幹細胞培養方法
EP3429360A4 (en) * 2016-03-16 2019-08-28 Cell Medicine, Inc. MESENCHYMAL STEM CELLS WITH IMPROVED EFFICACY
KR20220126789A (ko) 2016-07-18 2022-09-16 브레인스톰 셀 세라퓨틱스 리미티드 근위축성 측색 경화증 (als)의 치료 방법
CN108559729B (zh) * 2018-02-05 2022-01-14 上海科技大学 Fam49基因及其编码蛋白的应用
JP2021520790A (ja) 2018-04-10 2021-08-26 ブレインストーム セル セラペウティクス リミテッド 細胞型特異的エキソソームおよびそれらの使用
US20220042099A1 (en) * 2018-10-18 2022-02-10 Quadrant Biosciences Inc. Molecular and functional characterization of early-stage parkinson's disease and treatments therein
WO2020086667A1 (en) 2018-10-25 2020-04-30 American University Method for promoting adipocyte differentiation and obesity-related disease treatment
CN111979186B (zh) * 2020-08-21 2022-04-08 遵义医科大学附属医院 一种快速高效体外扩增人间充质干细胞的方法及应用
US20220347349A1 (en) * 2021-04-30 2022-11-03 Stemcellago Inc. Engineered cartilage

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
JP3948971B2 (ja) 2001-08-30 2007-07-25 サンバイオ,インコーポレイティド Notch遺伝子の導入を用いて骨髄間質細胞を神経細胞及び骨格筋細胞に分化・誘導する方法
US7682825B2 (en) * 2002-02-06 2010-03-23 Sanbio, Inc. Differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
IL152905A0 (en) 2002-11-17 2003-06-24 Univ Ramot Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease
WO2006134602A2 (en) 2005-06-16 2006-12-21 Ramot At Tel Aviv University Ltd. Isolated cells and populations comprising same for the treatment of cns diseases
US20100021434A1 (en) 2005-12-08 2010-01-28 Ramot At Tel Aviv University Ltd. Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases
DK2285951T3 (en) * 2008-05-28 2018-10-22 Univ Ramot TREATMENT OF CNS DISEASES OF CNS DISEASES
US20100184033A1 (en) 2008-07-16 2010-07-22 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
US10485829B2 (en) * 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
ES2600321T3 (es) * 2011-08-04 2017-02-08 Ethianum Betriebsgesellschaft Mbh & Co. Kg Medios para la regeneración del hígado
DE102011121982B3 (de) * 2011-12-22 2013-04-18 Dietmar Hopp Stiftung GmbH Mesenchymale Stammzellen aus Fettgewebe (ADSC) zur Rekonstruktion von Haut und Weichteilgewebe
WO2014011407A2 (en) * 2012-07-12 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2014024183A1 (en) 2012-08-06 2014-02-13 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
CA2937305C (en) 2014-02-11 2020-12-15 Brainstorm Cell Therapeutics Ltd. Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells

Also Published As

Publication number Publication date
JP6628253B2 (ja) 2020-01-08
EP3105587A1 (en) 2016-12-21
IL246943A0 (en) 2016-09-29
US20160334392A1 (en) 2016-11-17
IL246943B (en) 2020-05-31
WO2015121859A8 (en) 2015-10-08
BR112016018489A2 (pt) 2017-08-08
CA2937305A1 (en) 2015-08-20
WO2015121859A1 (en) 2015-08-20
JP2017511876A (ja) 2017-04-27
US10564149B2 (en) 2020-02-18
HK1232296A1 (en) 2018-01-05
EP3105587B1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
CA2937305C (en) Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells
Bárcia et al. What makes umbilical cord tissue‐derived mesenchymal stromal cells superior immunomodulators when compared to bone marrow derived mesenchymal stromal cells?
Heo et al. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue
US20120107413A1 (en) Pre-natal mesenchymal stem cells
US20100105132A1 (en) Human Mesenchymal stem cells and preparation thereof
KR102124837B1 (ko) 기질 줄기 세포
CA2954505C (en) Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors
Branscome et al. Stem cell extracellular vesicles and their potential to contribute to the repair of damaged CNS cells
Karaöz et al. A comprehensive characterization study of human bone marrow mscs with an emphasis on molecular and ultrastructural properties
CA3145681A1 (en) Priming media and methods for stem cell culture and therapy
EP2596097A2 (en) High telomerase activity bone marrow mesenchymal stem cells, methods of producing the same and pharmaceuticals and treatment methods based thereon
CN101198691B (zh) 多种系干细胞的分离
KR20110095218A (ko) PI3K/AKT/GSK3 경로를 통해 성체줄기세포의 증식, 다분화능 및 재프로그래밍을 촉진하는 CD49f
AU2013389474B2 (en) Transplantation adjuvant in cell therapy using neural progenitor cells
CN105343894A (zh) 高效分泌前列腺素e2(pge2)的重组间充质干细胞及其应用
Dao et al. Comparing the immunosuppressive potency of naïve marrow stromal cells and Notch-transfected marrow stromal cells
Szade et al. CD45− CD14+ CD34+ murine bone marrow low-adherent mesenchymal primitive cells preserve multilineage differentiation potential in long-term in vitro culture
AU2023353929A1 (en) T cell production method
HK1232296B (en) Method of qualifying cells
Zhang et al. miR-21 contributes to human amniotic membrane-derived mesenchymal stem cell growth and human amniotic membrane-derived mesenchymal stem cell-induced immunoregulation
Dubon et al. Substance P modulates properties of bone marrow-derived mesenchymal stem cells
CN113667635A (zh) 无异源培养基及使用其扩增间充质干细胞的方法
Sandhu Master of Veterinary
WO2017032612A1 (en) Stem cells with enhanced clonogenic, migratory and homing capacities
Guan et al. In vitro differentiation of human skin-derived mesenchymal stem cells into lymphocytes: Possibility evaluation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200204

MKLA Lapsed

Effective date: 20220211